BSN HESI 315 Pharmacology PREP Exam New 2026/2027 | Questions & Answers with Detailed Rationales | 100% Correct Grade A Study Guide | HESI & NCLEX-RN® Pharmacology Review PDF

INSTANT PDF DOWNLOAD — This is the comprehensive Pharmacology PREP Exam preparation guide for BSN HESI 315 (New 2026/2027), featuring questions and answers with detailed rationales. Designed for nursing students preparing for the HESI Pharmacology Exam and NCLEX-RN®, this resource consolidates the essential pharmacology concepts required to achieve a high score on the HESI Pharmacology exam and pass the NCLEX-RN® on the first attempt. The guide is meticulously aligned with HESI testing blueprints, NCLEX-RN® test plan, and current evidence-based pharmacology standards. This verified resource provides comprehensive coverage of key HESI Pharmacology exam topics, including: Pharmacokinetics (absorption—bioavailability, first-pass effect (oral medications metabolized by liver before reaching systemic circulation, reduced bioavailability, alternative routes (IV, IM, sublingual, rectal) bypass first-pass), factors affecting absorption (route of administration (IV fastest), blood flow, pain/stress, food, pH, surface area, motility), distribution—volume of distribution (high Vd: drug distributes to tissues, long half-life (digoxin, amiodarone); low Vd: remains in plasma, short half-life (warfarin)), protein binding (highly protein-bound drugs (90%): warfarin (99%), phenytoin (90-95%), valproate (90%), ceftriaxone (85-95%), diazepam (99%), only free (unbound) drug active, drug-drug displacement interactions (warfarin + phenytoin, warfarin + valproate, warfarin + sulfonamides increase free drug, toxicity risk), blood-brain barrier (lipid-soluble drugs cross (benzodiazepines, opioids, antipsychotics, antidepressants), P-glycoprotein efflux pump), placental transfer (lipid-soluble, low molecular weight drugs cross (opioids, benzodiazepines, anticonvulsants, alcohol, nicotine), teratogenic risk highest first trimester), metabolism—liver (phase I (CYP450 system—oxidation, reduction, hydrolysis), phase II (conjugation—glucuronidation, acetylation, sulfation), CYP450 inducers (increase metabolism, decrease drug levels—rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort, smoking), CYP450 inhibitors (decrease metabolism, increase drug levels, risk toxicity—ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice, amiodarone, verapamil, diltiazem, cimetidine, fluconazole, omeprazole, fluoxetine, paroxetine, bupropion), genetic polymorphisms (CYP2D6 poor metabolizers: codeine ineffective, increased toxicity for metoprolol, carvedilol, haloperidol; CYP2D6 ultrarapid metabolizers: codeine toxicity (respiratory depression, death), contraindicated in breastfeeding; CYP2C19 poor metabolizers: clopidogrel resistance (increased stent thrombosis, MI, stroke); CYP2C9 poor metabolizers: warfarin sensitivity (reduce dose, monitor INR)), elimination—renal (glomerular filtration, tubular secretion, tubular reabsorption, drug interactions affecting renal elimination (NSAIDs + lithium (increased lithium levels, toxicity), ACEi/ARB + lithium, diuretics + lithium), half-life (time for drug concentration to decrease by 50%, determines dosing interval), steady state (reached after 4-5 half-lives, loading dose for drugs with long half-life (digoxin, amiodarone, phenytoin, warfarin)), therapeutic drug monitoring (indications: narrow therapeutic index (digoxin, lithium, phenytoin, valproate, carbamazepine, theophylline, aminoglycosides, vancomycin, cyclosporine, tacrolimus, warfarin (INR)), variable pharmacokinetics, non-adherence, toxicity), therapeutic index (TI = TD50/ED50, low TI (narrow therapeutic window, need monitoring: digoxin, lithium, phenytoin, warfarin, theophylline, aminoglycosides, vancomycin)), pharmacodynamics (receptor theory—agonist (activates receptor—albuterol (beta-2 agonist), morphine (mu-opioid agonist)), partial agonist (submaximal response—buprenorphine, aripiprazole), antagonist (blocks receptor—naloxone, flumazenil, metoprolol, losartan), potency (dose required for 50% of maximal effect (ED50), lower ED50 = more potent (fentanyl more potent than morphine)), efficacy (maximal effect (Emax), ceiling effect (ibuprofen analgesic ceiling 400-600 mg)), tolerance (decreased response over time, need higher dose (opioids, benzodiazepines, nicotine, alcohol)), dependence (physiological adaptation, withdrawal symptoms when stopped), addiction (psychological craving, compulsive use despite harm), adverse drug reactions—Type A (augmented, dose-dependent, predictable (anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, tachycardia, cognitive impairment), bleeding (anticoagulants, antiplatelets), hypoglycemia (insulin, sulfonylureas), orthostatic hypotension (alpha-blockers, TCAs), QT prolongation (amiodarone, sotalol, methadone, haloperidol (IV), ziprasidone, citalopram, levofloxacin, moxifloxacin, azithromycin, ondansetron—risk torsades de pointes, avoid with hypokalemia, hypomagnesemia, bradycardia, other QT-prolonging drugs)), Type B (bizarre, idiosyncratic, unpredictable—anaphylaxis (penicillin, sulfa drugs, latex, contrast media), Stevens-Johnson syndrome/TEN (allopurinol, carbamazepine, phenytoin, lamotrigine, sulfonamides, NSAIDs), DRESS (allopurinol, carbamazepine, phenytoin, lamotrigine, sulfonamides, vancomycin, minocycline)), Type C (continuous, long-term use—corticosteroid-induced osteoporosis, adrenal suppression, growth suppression, Cushing's syndrome; NSAID-induced gastric ulcer), Type D (delayed, time-related—tardive dyskinesia (antipsychotics, metoclopramide, prochlorperazine, promethazine), after months to years, potentially irreversible, prevention (lowest effective dose, shortest duration, regular AIMS monitoring), treatment (valbenazine (Ingrezza), deutetrabenazine (Austedo) VMAT2 inhibitors)), Type E (end of treatment, withdrawal—benzodiazepine withdrawal (anxiety, insomnia, seizures, delirium tremens-like, life-threatening, taper over weeks to months), opioid withdrawal (not life-threatening but severe (yawning, rhinorrhea, piloerection, mydriasis, muscle aches, abdominal cramps, nausea, vomiting, diarrhea, tachycardia, hypertension, fever, diaphoresis, insomnia, anxiety, craving), treatment (methadone, buprenorphine, clonidine, lofexidine)), corticosteroid withdrawal (adrenal insufficiency—fatigue, weakness, nausea, vomiting, hypotension, hypoglycemia, hyponatremia, hyperkalemia, taper slowly, stress dose for surgery/illness), beta-blocker withdrawal (rebound hypertension, tachycardia, angina, MI, arrhythmias, sudden death, taper over 1-2 weeks), clonidine withdrawal (rebound hypertension, tachycardia, agitation, anxiety, headache, nausea, vomiting, life-threatening hypertensive crisis, taper over 2-7 days)), drug interactions—pharmacodynamic (additive (opioid + benzodiazepine (respiratory depression), alcohol + benzodiazepine (CNS depression), ACEi + ARB (hyperkalemia, hypotension, renal impairment)), synergistic (TMP-SMX (trimethoprim + sulfamethoxazole), piperacillin + tazobactam)), antagonistic (naloxone + morphine, vitamin K + warfarin)), pharmacokinetic—absorption (antacids decrease absorption of tetracyclines, fluoroquinolones, bisphosphonates, iron, levothyroxine—separate by 2-4 hours), distribution (protein-binding displacement (warfarin + phenytoin, warfarin + valproate, warfarin + sulfonamides, phenytoin + valproate—monitor INR, levels, toxicity)), metabolism (CYP450 inducers: rifampin + oral contraceptives (unintended pregnancy), rifampin + warfarin (decreased INR, thrombosis), carbamazepine/phenytoin/phenobarbital + warfarin, carbamazepine/phenytoin/phenobarbital + oral contraceptives, St. John's wort + oral contraceptives, St. John's wort + warfarin, St. John's wort + cyclosporine/tacrolimus (graft rejection), smoking + theophylline, smoking + olanzapine, clozapine, haloperidol (smokers need higher doses), CYP450 inhibitors: clarithromycin/erythromycin + simvastatin/atorvastatin/lovastatin (increased statin levels, myopathy, rhabdomyolysis, avoid or use pravastatin, rosuvastatin, fluvastatin, pitavastatin), clarithromycin/erythromycin + colchicine (increased colchicine levels, GI toxicity, myopathy, neuropathy, pancytopenia, avoid or reduce colchicine dose), grapefruit juice + simvastatin/atorvastatin/lovastatin (increased levels, myopathy, rhabdomyolysis, avoid grapefruit juice), fluconazole + warfarin (increased INR, bleeding, monitor INR, reduce warfarin dose), fluconazole + phenytoin (increased phenytoin levels, nystagmus, ataxia, drowsiness), valproate + lamotrigine (valproate doubles lamotrigine levels, increased risk serious rash (SJS/TEN), start lamotrigine at half dose when adding to valproate), amiodarone + warfarin (increased INR, bleeding, reduce warfarin dose by 30-50%, monitor INR closely), amiodarone + digoxin (increased digoxin levels, toxicity (nausea, vomiting, visual changes, bradycardia, arrhythmias), reduce digoxin dose by 50%, monitor levels), cimetidine + warfarin (increased INR, bleeding, use famotidine or ranitidine (no CYP inhibition)), fluoxetine/paroxetine/bupropion + tamoxifen (CY